When You Give Blood What Do They Check For?

Every unit of donated blood goes through a battery of tests before it reaches a patient. At minimum, your donation will be checked for your blood type, your hemoglobin level, and a panel of infectious diseases including HIV, hepatitis B, hepatitis C, syphilis, and several other pathogens. The exact list varies slightly by country and sometimes by region within a country, but the core screening panel is remarkably consistent across high-income nations. What might surprise you is how much testing happens after you leave the donation chair, and how the results can occasionally loop back to affect you personally.

The Quick Check Before You Donate

Before a needle goes into your arm, the blood center runs a fast hemoglobin check. This is typically a fingerstick: a drop of blood from your fingertip is placed in a small portable analyzer. The goal is to make sure you are not anemic, because drawing a full unit of blood from someone whose hemoglobin is already low would be harmful. Men generally need a hemoglobin of at least 13.0 g/dL, and women need at least 12.5 g/dL, though thresholds vary slightly between organizations. Fingerstick readings tend to run a little higher than a proper venous blood draw, so the test occasionally lets someone through who is borderline or turns away someone who would actually be fine.¹ It is a rough gatekeeper, not a precise lab value.

You also fill out a donor health questionnaire. This is not a formality. The questionnaire asks about recent travel, medications, sexual history, tattoos, piercings, and prior infections. Some diseases that can be transmitted through blood have no reliable lab test, or the available tests are not practical for mass screening. Variant Creutzfeldt-Jakob disease, the human form of mad cow disease, is the classic example: there is no approved blood test for it, so the questionnaire is the only filter.² Travel-related deferrals for malaria risk work on a similar principle. These questions are the first layer of protection, and they catch threats that laboratory testing cannot.

Blood Typing and Antibody Screening

Once your blood is collected, one of the first laboratory steps is determining your ABO group and Rh status. You probably already know whether you are A, B, AB, or O and whether you are Rh-positive or Rh-negative, but the blood bank confirms it every time because a mismatch can be fatal for a transfusion recipient. Beyond the familiar ABO and Rh systems, scientists have identified over 30 distinct blood group systems based on different antigens on the surface of red blood cells.³ Most of these rarely cause problems, but some can trigger serious reactions, especially in patients who receive many transfusions or in newborns.

Blood centers also screen for unexpected red cell antibodies in the donated blood. If a donor has developed antibodies against red cell antigens they lack, those antibodies can attack the recipient’s own red blood cells once transfused. This is a particular concern for patients receiving large-volume transfusions and for pediatric patients, where even a small amount of incompatible antibody can do damage.⁴

The Core Viral Panel

The infectious disease tests are the heart of post-donation screening. In the United States and most of Europe, every donation is tested for HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) using two complementary approaches. The first is serological testing, which looks for antibodies or antigens that your immune system produces in response to infection. The second is nucleic acid testing, or NAT, which directly detects the genetic material of the virus itself.

NAT is the more sensitive of the two and was a major leap forward in blood safety. Because it detects viral DNA or RNA rather than waiting for the body’s immune response to kick in, it can catch infections during the “window period,” the days or weeks right after someone is infected when they are already contagious but have not yet produced detectable antibodies. A single triplex NAT assay can simultaneously screen for HIV RNA, HCV RNA, and HBV DNA in one run.⁵ This approach has intercepted window-period infections that serological testing alone would have missed.

For hepatitis B specifically, the testing is layered. Blood centers typically run three separate markers: hepatitis B surface antigen (HBsAg), antibodies to the hepatitis B core antigen (anti-HBc), and HBV DNA by NAT. A large U.S. study covering about 22 million donations over four years found that combining all three markers identified active HBV infections at a rate of roughly 9 per hundred thousand donations, and each marker caught cases the others missed.⁶ That redundancy is deliberate. No single test is perfect, and the consequences of missing an infection are severe enough that blood banks stack multiple assays on top of each other.

HTLV and Syphilis

Two other longstanding items on the screening panel are human T-lymphotropic virus (HTLV) and syphilis. HTLV types I and II are retroviruses that can be transmitted through blood products and are associated with certain leukemias and neurological disease. Blood banks screen for HTLV using immunoassay-based tests, typically starting with a sensitive screening assay and following up reactive samples with a confirmatory method such as a Western blot.⁷ HTLV screening also feeds into broader public health surveillance, since blood donation testing sometimes provides the clearest picture of how widely the virus circulates in a population.⁸

Syphilis screening is one of the oldest tests in the blood-banking toolkit. Modern blood centers use automated immunoassays that detect antibodies to Treponema pallidum, the bacterium that causes syphilis.⁹ Some centers have moved to a sequential two-assay approach: an initial high-sensitivity screen followed by a second, independent immunoassay on any reactive samples. A large-scale evaluation of this approach across nearly 1.8 million donor samples found a false-positive rate on the initial screen of only about 0.08 percent.¹⁰ That low false-positive rate matters, because a reactive syphilis test leads to donor deferral and notification, and no one wants to receive that letter unnecessarily.

Parasites and Region-Specific Threats

Not every pathogen on the screening list applies everywhere. Some tests are triggered by geography, either yours or the local epidemiology of the region where you are donating.

Chagas disease, caused by the parasite Trypanosoma cruzi, is a prime example. It is endemic in parts of Central and South America and affects an estimated 290,000 people living in the United States.¹¹ U.S. blood centers now include Chagas screening on the routine panel, typically testing each donor at least once. The screening strategy uses a high-sensitivity assay to catch as many true positives as possible, followed by a high-specificity confirmatory test to weed out false alarms.¹² In countries outside the Americas, only donors with relevant travel or birth history are typically tested.

Babesia microti, a tick-borne parasite, became a newer addition to U.S. screening in endemic states. The American Red Cross began testing all donations in affected areas of the Northeast and Midwest in 2020, using a combination of antibody and DNA-based assays.¹³ Before routine testing was adopted, transfusion-transmitted babesiosis was one of the most frequently reported transfusion-associated infections in the United States.¹⁴

West Nile virus is another seasonal and regional concern. Because the virus circulates through mosquitoes, the risk fluctuates with the time of year and where mosquitoes are active. Blood centers in affected areas use NAT-based screening during transmission season to catch viremic donors who feel perfectly fine but are carrying the virus in their blood.¹⁵

Malaria presents a different challenge. In most high-income countries where malaria is not endemic, the primary defense is deferral based on travel history rather than laboratory testing of every donation. European regulations, for instance, require a waiting period of several months to several years for donors who have traveled to or lived in malaria-endemic regions.¹⁶ In countries where malaria is common, blood banks may use rapid diagnostic tests or molecular assays to screen donors directly, since deferring everyone with potential exposure would eliminate most of the donor pool.¹⁷

Bacterial Contamination of Platelets

Platelets are the blood component most vulnerable to bacterial contamination because they are stored at room temperature, which lets bacteria grow. Whole blood and red blood cells are refrigerated, which suppresses most bacterial growth, but platelets lose their function if chilled. Blood centers address this with a combination of strategies: careful skin disinfection at the needle site, diverting the first few milliliters of the collection away from the main bag to reduce skin-plug bacteria, and, increasingly, direct culture-based testing of platelet units.¹⁸

In the U.S., primary culture of platelet units has been standard since 2004. A sample is drawn from the platelet bag about 24 hours after collection and placed in an aerobic culture bottle. The U.K. adopted a different protocol starting in 2011, using larger sample volumes and both aerobic and anaerobic culture bottles drawn 36 to 48 hours after collection. Some centers also use rapid secondary tests closer to the time of transfusion, adding yet another checkpoint before the platelets reach a patient.

What Happens When a Test Comes Back Positive

A reactive screening result does not automatically mean you are infected. Initial screening assays are deliberately calibrated to be very sensitive, which means they will occasionally flag samples that turn out to be false positives. The blood center’s next step is to run confirmatory or supplemental tests on the flagged sample. For hepatitis B core antibody, for example, a study found that about 80 percent of initially reactive samples were confirmed positive by a secondary assay and neutralization test, while a small number of samples gave contradictory results across different assays and remained indeterminate even after extensive additional testing.¹⁹

If the confirmatory test is positive, the blood unit is discarded and you are notified, usually by letter. The notification will include information about the finding and instructions to see your doctor for follow-up. You will also typically be deferred from future donations, either temporarily or permanently depending on the pathogen. For Chagas disease, donors who screen positive are deferred and given information about next steps, though linking them to actual clinical care has been an ongoing challenge.¹¹ If supplemental testing shows the initial screen was a false positive, you may be reinstated as an eligible donor, but this process can take time.

How Safe Is the Blood Supply After All This Testing

The layered approach of questionnaire screening, serological testing, and NAT has driven the residual risk of a contaminated unit making it into the blood supply to extraordinarily low levels. In Italy, a seven-year analysis estimated the chance of an HIV-positive unit slipping through at roughly one in 1.9 million donations, and for hepatitis C, about one in 13 million donations.²⁰ For hepatitis B, a separate Italian study covering 2009 to 2018 estimated the risk at about one in 2.6 million donations when combining both acute window-period infections and occult HBV infections.²¹

These numbers are not zero, but they are vanishingly small. The residual risk comes almost entirely from donations made during the narrow window period when a newly infected donor has not yet developed detectable levels of virus. NAT shortened those windows dramatically, but a gap of a few days still exists for each pathogen. Residual risk also varies by country depending on the prevalence of infections in the general population. A Lithuanian study covering 2004 to 2018 documented higher residual risk figures overall, but even there, the trend was consistently downward over the study period.²²

Pathogen Reduction Technology

Testing, no matter how thorough, cannot catch every possible threat. New or re-emerging pathogens may appear before screening tests for them even exist. To address that gap, some blood centers have adopted pathogen reduction technology, which treats blood components with chemicals or ultraviolet light to inactivate viruses, bacteria, and parasites directly.²³ Three photochemical systems currently in use rely on amotosalen, riboflavin, or UVC light, each of which damages the nucleic acids of pathogens so they cannot replicate.²⁴

Pathogen reduction is not a replacement for testing; it works best as an additional layer. During outbreaks of infectious diseases for which no screening test exists, it becomes especially valuable. The European Centre for Disease Prevention and Control has recognized it as a blood safety intervention that can be deployed during outbreaks precisely because it does not require identifying the specific pathogen in advance.²⁵ The technology works well for platelets and plasma, though applying it to red blood cells has been technically harder and is not yet widely available. Cost remains the main barrier to broader adoption.

Iron and Ferritin Monitoring for Repeat Donors

The tests described above are all about protecting the blood recipient. But some blood centers have started adding a test that protects you, the donor: a ferritin level. Ferritin is a protein that reflects your body’s iron stores. Every time you donate whole blood, you lose a significant amount of iron, and frequent donors can quietly become iron-depleted even if their hemoglobin stays above the minimum threshold for donation. The standard pre-donation hemoglobin check does not catch early iron depletion, because hemoglobin is the last thing to drop when iron stores are running low.

A study tracking new whole blood donors over repeated donations found that those with ferritin levels below 30 ng/mL had roughly 1.4 to 3.8 times higher odds of developing iron deficiency or failing the hemoglobin check at their next visit compared to donors with ferritin above 30. Ferritin levels in the range of 25 to 30 ng/mL offered a useful balance of sensitivity and specificity for predicting who would run into trouble next time.²⁶ Not all blood centers measure ferritin routinely yet, but the practice is growing, and some now use ferritin results to recommend longer intervals between donations or iron supplementation for repeat donors whose stores are dipping.

If your blood center does not check ferritin, it is worth asking your regular doctor to run it occasionally if you donate frequently. The symptoms of low iron without anemia, including fatigue, brain fog, and restless legs, are vague enough that many repeat donors chalk them up to other causes. Knowing your ferritin level lets you make informed decisions about how often to donate without quietly depleting yourself.